Patents Assigned to PELEMED CO., LTD.
  • NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF
    Publication number: 20240010635
    Abstract: SUMMARY OF THE INVENTION The present invention relates to novel indirubin derivatives having heterobicyclic moieties, and use thereof as fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinase inhibitors. The compound of the present invention effectively inhibits the activity of FLT3 and RET kinases, and thus may be useful for preventing or treating mutant FLT3 and mutant RET-related diseases, particularly acute myeloid leukemia.
    Type: Application
    Filed: December 23, 2022
    Publication date: January 11, 2024
    Applicant: Pelemed Co., Ltd.
    Inventors: Soo Yeon Jang, Myung Jin Kim, Jin Hee Park, So Deok Lee, Su Jin Oh, Eun Ji Lee, Yong Chul Kim, Woo Chan Kim, Je Heon Lee
  • NOVEL CAPSID ASSEMBLY INHIBITOR
    Publication number: 20230399320
    Abstract: The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 14, 2023
    Applicant: Pelemed Co., Ltd.
    Inventors: Yong Chul Kim, Sung Gyoo Park, Jiwon Seo, Woo Chan Kim, Jae Hoon Jung, Yuri Cho, Yoon Jun Kim
  • Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
    Patent number: 11370779
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used, it can effectively inhibit the activity of FLT3 kinase and can be usefully used to prevent or treat acute myeloid leukemia or metastatic breast cancer.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: June 28, 2022
    Assignee: PELEMED CO., LTD.
    Inventors: Yong Chui Kim, Pyeong-Hwa Jeong
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER
    Publication number: 20200270229
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used, it can effectively inhibit the activity of FLT3 kinase and can be usefully used to prevent or treat acute myeloid leukemia or metastatic breast cancer.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 27, 2020
    Applicant: PELEMED CO., LTD.
    Inventors: Yong Chul Kim, Pyeong-Hwa Jeong